AU668159B2 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds Download PDF

Info

Publication number
AU668159B2
AU668159B2 AU39807/93A AU3980793A AU668159B2 AU 668159 B2 AU668159 B2 AU 668159B2 AU 39807/93 A AU39807/93 A AU 39807/93A AU 3980793 A AU3980793 A AU 3980793A AU 668159 B2 AU668159 B2 AU 668159B2
Authority
AU
Australia
Prior art keywords
alkyl
optionally substituted
cycloalkyl
compound according
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU39807/93A
Other languages
English (en)
Other versions
AU3980793A (en
Inventor
John Fairhurst
Terrence Michael Hotten
David Edward Tupper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Industries Ltd
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of AU3980793A publication Critical patent/AU3980793A/en
Application granted granted Critical
Publication of AU668159B2 publication Critical patent/AU668159B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU39807/93A 1992-05-29 1993-05-26 Pharmaceutical compounds Ceased AU668159B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB9211379 1992-05-29
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds
GB9309025 1993-04-30

Publications (2)

Publication Number Publication Date
AU3980793A AU3980793A (en) 1993-12-02
AU668159B2 true AU668159B2 (en) 1996-04-26

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39807/93A Ceased AU668159B2 (en) 1992-05-29 1993-05-26 Pharmaceutical compounds

Country Status (21)

Country Link
EP (1) EP0582368B1 (enExample)
JP (1) JP3219541B2 (enExample)
CN (1) CN1043994C (enExample)
AT (1) ATE198891T1 (enExample)
AU (1) AU668159B2 (enExample)
CA (1) CA2097016A1 (enExample)
CZ (1) CZ282783B6 (enExample)
DE (1) DE69329887T2 (enExample)
DK (1) DK0582368T3 (enExample)
ES (1) ES2153373T3 (enExample)
FI (1) FI101538B1 (enExample)
GR (1) GR3035587T3 (enExample)
HU (1) HU218278B (enExample)
IL (1) IL105827A (enExample)
MX (1) MX9303124A (enExample)
MY (1) MY109943A (enExample)
NO (1) NO305125B1 (enExample)
NZ (1) NZ247703A (enExample)
PT (1) PT582368E (enExample)
RU (1) RU2125574C1 (enExample)
TW (1) TW268005B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
PL329217A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Pain relieving method
BR9708145A (pt) * 1996-03-25 1999-07-27 Lilly Co Eli Processo para tratamento de dor de enxaqueca
PL187926B1 (pl) * 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
AU720366B2 (en) * 1996-09-23 2000-06-01 Eli Lilly And Company Olanzapine dihydrate D
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
JP2001501207A (ja) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー コーティングされた粒子製剤
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
CA2882560C (en) 2012-08-21 2020-10-27 Ortho-Clinical Diagnostics, Inc. Haptens of risperidone and paliperidone for use in immunoassays
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
PL2888373T3 (pl) 2012-08-21 2018-08-31 Janssen Pharmaceutica Nv Przeciwciała dla arypiprazolu i ich zastosowanie
PT3305784T (pt) 2012-08-21 2020-10-23 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
WO2014031662A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine and use thereof
PL2888286T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
ES2870004T3 (es) 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
ES3057437T3 (en) 2012-08-21 2026-03-02 Janssen Pharmaceutica Nv Antibodies to olanzapine haptens and use thereof
ES2701062T3 (es) * 2012-08-21 2019-02-20 Janssen Pharmaceutica Nv Haptenos de olanzapina
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用
CN108368180B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 喹硫平的抗体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1533235A (en) * 1974-11-26 1978-11-22 Lilly Industries Ltd Benzodiazepine derivatives
AU7518691A (en) * 1990-04-25 1991-11-07 Eli Lilly And Company Limited 2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno(2,3-b)(1,5)- benzodiazepine and process for making the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569730A5 (enExample) * 1972-04-04 1975-11-28 Wander Ag Dr A
US4061752A (en) * 1975-08-06 1977-12-06 Sandoz Ltd. 6-Piperazino-11-methylene-dibenzazepines[b,e]
SE7610219L (sv) * 1975-09-24 1977-03-25 Sandoz Ag Nya dibenso /b,e//1,4/ diazepiner
CH624682A5 (enExample) * 1976-11-10 1981-08-14 Sandoz Ag
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1533235A (en) * 1974-11-26 1978-11-22 Lilly Industries Ltd Benzodiazepine derivatives
AU7518691A (en) * 1990-04-25 1991-11-07 Eli Lilly And Company Limited 2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno(2,3-b)(1,5)- benzodiazepine and process for making the same

Also Published As

Publication number Publication date
IL105827A0 (en) 1993-09-22
CZ102493A3 (en) 1993-12-15
MY109943A (en) 1997-10-31
IL105827A (en) 1997-02-18
DK0582368T3 (da) 2001-02-05
CN1043994C (zh) 1999-07-07
DE69329887D1 (de) 2001-03-01
JP3219541B2 (ja) 2001-10-15
FI101538B (fi) 1998-07-15
NO931917D0 (no) 1993-05-26
FI101538B1 (fi) 1998-07-15
CA2097016A1 (en) 1993-11-30
HU9301579D0 (en) 1993-09-28
HU218278B (en) 2000-07-28
CN1085903A (zh) 1994-04-27
PT582368E (pt) 2001-05-31
NO931917L (no) 1993-11-30
TW268005B (enExample) 1996-01-11
CZ282783B6 (cs) 1997-10-15
ATE198891T1 (de) 2001-02-15
JPH0687862A (ja) 1994-03-29
NO305125B1 (no) 1999-04-06
FI932445A0 (fi) 1993-05-28
FI932445L (fi) 1993-11-30
ES2153373T3 (es) 2001-03-01
EP0582368B1 (en) 2001-01-24
HUT66180A (en) 1994-09-28
DE69329887T2 (de) 2001-05-23
EP0582368A1 (en) 1994-02-09
MX9303124A (es) 1993-11-01
GR3035587T3 (en) 2001-06-29
NZ247703A (en) 1995-07-26
AU3980793A (en) 1993-12-02
RU2125574C1 (ru) 1999-01-27

Similar Documents

Publication Publication Date Title
EP0582368B1 (en) Thienobenzodiazepine derivatives for treatment of CNS disorders
US5605897A (en) 2-methyl-thieno-benzodiazepine
US6008216A (en) Process for preparing 2-methyl-thieno-benzodiazepine
US6034078A (en) Thienobenzodiazepine compounds
JP4709849B2 (ja) アルツハイマー病治療のためのグリシントランスポーターｉ（ｇｌｙｔ−１）インヒビターとしての二環式及び三環式置換フェニルメタノン類
US5229382A (en) 2-methyl-thieno-benzodiazepine
JP2527860B2 (ja) チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン誘導体及び該誘導体を含有する抗精神病薬組成物
US5817656A (en) Mental disorders
WO2015086499A1 (en) Imidazopyrimidine derivatives as modulators of tnf activity
EP3080111A1 (en) Imidazopyridine derivatives as modulators of tnf activity
WO2008060190A2 (fr) Ligand des récepteurs 5-ht6, composition pharmaceutique et procédé de fabrication et d'utilisation
US4963558A (en) Pyrazolo-[3,4-g]isoquinoline derivatives useful to treat CNS disorders
SK15612002A3 (sk) Azabicyklické karbamáty, spôsob ich prípravy a farmaceutické prostriedky, ktoré ich obsahujú ako účinné látky
EP0655451B1 (en) Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia
NZ250682A (en) Heterotricyclyloxoalkyl substituted piperidine, piperazine and 4-benzylpiperidine derivatives, their preparation and pharmaceutical compositions
US5817655A (en) Methods of treatment using a thieno-benzodiazepine
AU2241400A (en) Novel thiazolobenzoimidazole derivative
US5817657A (en) Psychoactive substance disorders
CZ290678B6 (cs) 3-Substituované 3,4,5,7-tetrahydropyrrolo[3´,4´: 4,5]thieno[2,3-d]pyrimidinové deriváty, způsob jejich přípravy a použití
JP7733578B2 (ja) Ｕｓｐ１９の抑制
US4673674A (en) Diazepinoindoles useful for treating depression, schizophrenia, social withdrawal or anxiety and pharmaceutical compositions containing them
KR100273622B1 (ko) 티에노벤조디아제핀 유도체, 이의 제조방법 및 이를 포함하는 약제학적 제형
IL285511B2 (en) Pentacyclic heterocyclic compounds and pharmaceutical compositions comprising them for the treatment of cognitive dysfunction
CN102947301A (zh) 喹嗪烷和吲嗪烷衍生物
AU697529B2 (en) Antipsychotic method

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired